Contineum Therapeutics (CTNM) Evercore ISI 8th Annual HealthCONx Conference summary

Key accomplishments and clinical progress

• Executed four clinical studies in the first full year as a public company, including a phase 1b PET receptor occupancy study for PIPE-791 and full enrollment of a phase 1b exploratory study in chronic pain, with data expected in the first half of next year.

• Reported VISTA data for PIPE-307 in relapsing-remitting MS, missing the primary endpoint but providing valuable insights into M1 receptor antagonism.

• Preparing to launch a phase two proof-of-concept study in idiopathic pulmonary fibrosis (IPF) with PIPE-791, considered a highlight for 2026.

Scientific rationale and differentiation

• LPA1 receptor antagonism targets fibrosis and inflammation in IPF, chronic pain, and progressive MS by inhibiting fibroblast recruitment and neuroinflammation.

• PIPE-791 offers high receptor occupancy, QD dosing, and a favorable PK profile compared to competitors, aiming for best-in-class efficacy.

• Differentiation from BMS’s LPA1 includes once-daily dosing, higher target coverage, and potentially better safety and tolerability.

Market landscape and opportunity

• Current IPF treatments have significant tolerability issues, leading to high discontinuation rates and an unmet need for safer, more effective therapies.

• The market is considered untapped, with Ofev generating over $4 billion in annual sales despite its limitations.

• LPA1 antagonists are positioned to become the backbone of IPF and PPF therapy, with potential for polypharmacy approaches.